Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis
Jenying Deng, … , Rolf A. Brekken, Jason B. Fleming
Jenying Deng, … , Rolf A. Brekken, Jason B. Fleming
Published July 8, 2021
Citation Information: JCI Insight. 2021;6(17):e146133. https://doi.org/10.1172/jci.insight.146133.
View: Text | PDF
Research Article Oncology

DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis

  • Text
  • PDF
Abstract

Pancreatic ductal adenocarcinoma (PDAC) tumors are characterized by a desmoplastic reaction resulting in dense deposition of collagen that is known to promote cancer progression. A central mediator of protumorigenic collagen signaling is the receptor tyrosine kinase discoid domain receptor 1 (DDR1). DDR1 is a critical driver of a mesenchymal and invasive cancer cell PDAC phenotype. Previous studies have demonstrated that genetic or pharmacologic inhibition of DDR1 reduces PDAC tumorigenesis and metastasis. Here, we investigated whether DDR1 signaling has cancer cell nonautonomous effects that promote PDAC progression and metastasis. We demonstrate that collagen-induced DDR1 activation in cancer cells is a major stimulus for CXCL5 production, resulting in the recruitment of tumor-associated neutrophils (TANs), the formation of neutrophil extracellular traps (NETs), and subsequent cancer cell invasion and metastasis. Moreover, we have identified that collagen-induced CXCL5 production was mediated by a DDR1/PKCθ/SYK/NF-κB signaling cascade. Together, these results highlight the critical contribution of the collagen I–DDR1 interaction in the formation of an immune microenvironment that promotes PDAC metastasis.

Authors

Jenying Deng, Yaan Kang, Chien-Chia Cheng, Xinqun Li, Bingbing Dai, Matthew H. Katz, Taoyan Men, Michael P. Kim, Eugene A. Koay, Huocong Huang, Rolf A. Brekken, Jason B. Fleming

×

Figure 9

PKCθ/SYK/NF-κB pathway involved in DDR1-induced CXCL5 production, NET formation from neutrophils, and enhanced cancer cell invasion.

Options: View larger image (or click on image) Download as PowerPoint
PKCθ/SYK/NF-κB pathway involved in DDR1-induced CXCL5 production, NET fo...
(A) qPCR results were used to quantify enrichment of NF-κB P65 at the CXCL5 promoter using ChIP assay in MDA-PATC 148 cells with DDR1 knockdown. Data are mean ± SD. n = 3, 3 independent experiments; 1-way ANOVA with Sidak post hoc testing. ***P < 0.001. (B) Phospho-NF-κB P65, phospho-PKCθ, and phospho-SYK were analyzed by western blotting in MDA-PATC 148 cells with DDR1 knockdown. (C) Phospho-NF-κB P65, phospho-PKCθ, and phospho-SYK were analyzed by western blotting in MDA-PATC 148 cells with or without SYK inhibitor and PKC inhibitor pretreatment. (D and E) NET structures were analyzed by immunofluorescence staining using DAPI (blue), anti-NE (red), and anti–histone H3 (green) mAbs. (D) In MDA-PATC 148 cells with CCM from MDA-PATC 148 with IκB super-repressor mutation/collagen I, treatment for 18 hours. (E) In MDA-PATC 148 cells with MDA-PATC 148, with or without SYK inhibitor and PKC inhibitor pretreatment/collagen I, treatment for 18 hours. Scale bar: 50 μm. The NET quantification is displayed as NET histone area (μm2) per field, 6 fields per group. (F and G) The number of invaded cells were analyzed by immunofluorescence staining using DAPI and calculated based on the number of cells found in 6 fields per chamber. (F) In MDA-PATC 148 cells with NCCM from MDA-PATC 148 cells with IκB super-repressor mutation/neutrophils/collagen I, treatment for 18 hours. (G) In MDA-PATC 148 cells with NCCM from MDA-PATC 148/collagen I/SYK or PKC inhibitor, treatment for 18 hours. (D–G) Data are mean ± SD. n = 5–6, 3 independent experiments; 1-way ANOVA with Sidak post hoc testing. *P < 0.05;**P < 0.01; ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts